MARKET

GNMSF

GNMSF

Genmab A/S
OTCPK
298.00
NaN%
Opening 09:30 03/28 EDT
OPEN
--
PREV CLOSE
298.00
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
500.92
52 WEEK LOW
262.00
MARKET CAP
19.47B
P/E (TTM)
30.48
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GNMSF last week (0318-0322)?
Weekly Report · 3d ago
Transactions in Connection with Share Buy-back Program
Denmark's Genmab A/S announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The program is expected to be completed no later than December 16, 2024. The company will buy back shares.
Barchart · 3d ago
Weekly Report: what happened at GNMSF last week (0311-0315)?
Weekly Report · 03/18 12:00
Completion of share buy-back program
Barchart · 03/18 04:49
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. It was decided to grant 12,847 restricted stock units to members of the Board and employees of the Company.
Barchart · 03/13 15:53
Passing of Genmab A/S’ Annual General Meeting
Genmab A/S held its Annual General Meeting in Copenhagen, Denmark on March 13, 2024. The Company's plans for 2024 were presented. The Annual Report for 2023 was endorsed by the previous auditors, PricewaterhouseCoopers. The Board of Directors approved the report.
Barchart · 03/13 10:13
Weekly Report: what happened at GNMSF last week (0304-0308)?
Weekly Report · 03/11 11:55
Transactions in connection with share buy-back program
Barchart · 03/11 04:42
More
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S stock information, including OTCPK: GNMSF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMSF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNMSF stock methods without spending real money on the virtual paper trading platform.